XML 16 R25.htm IDEA: XBRL DOCUMENT
v2.4.0.8

Collaboration and License Agreements - Additional Information 3 (Detail) (USD $) | 3 Months Ended | 6 Months Ended |  | 1 Months Ended | 3 Months Ended | 6 Months Ended |  | 3 Months Ended | 6 Months Ended |  | 1 Months Ended |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Jun. 30, 2014 | Jun. 30, 2014 | Dec. 31, 2013 | Jan. 31, 2014 Servier [Member] | Jun. 30, 2014 Servier [Member] | Jun. 30, 2013 Servier [Member] | Jun. 30, 2014 Servier [Member] | Jun. 30, 2013 Servier [Member] | Dec. 31, 2013 Servier [Member] | Jun. 30, 2014 Servier [Member] Second Right to Develop Collaboration [Member] | Jun. 30, 2013 Servier [Member] Second Right to Develop Collaboration [Member] | Jun. 30, 2014 Servier [Member] Second Right to Develop Collaboration [Member] | Jun. 30, 2013 Servier [Member] Second Right to Develop Collaboration [Member] | Dec. 31, 2013 Servier [Member] Second Right to Develop Collaboration [Member] | Jul. 31, 2014 Servier [Member] Subsequent Event [Member] | Jun. 30, 2014 Servier [Member] Maximum [Member] | Jun. 30, 2014 Servier [Member] Maximum [Member] Second Right to Develop Collaboration [Member]
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration agreement date |  |  |  |  |  |  | November 2011 |  |  |  |  | September 2012 |  |  |  |  |
Non-refundable payment |  |  |  |  |  |  | $ 20,000,000 |  |  |  |  | $ 20,000,000 |  |  |  |  |
Additional license grant fees | 15,000,000 | 15,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  | 30,000,000 | 65,000,000
Clinical milestone payments | 5,000,000 | 5,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  | 47,000,000 | 98,000,000
Regulatory milestone payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 140,000,000 | 300,000,000
Sales milestone payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 208,000,000 | 630,000,000
Expected period of development |  |  |  | 38 months |  |  | 27 months |  |  |  |  | 29 months |  |  |  |  |
Recognized revenue under agreement |  |  |  |  | 200,000 | 4,400,000 | 400,000 | 6,600,000 |  | 2,700,000 | 2,200,000 | 10,000,000 | 4,300,000 |  |  |  |
Deferred revenue |  |  |  |  | 400,000 |  | 400,000 |  | 900,000 | 19,400,000 |  | 19,400,000 |  | 9,400,000 |  |  |
License option fees received |  |  |  |  |  |  |  |  |  |  |  | 15,000,000 |  |  |  |  |
Clinical milestone payments received |  |  |  |  |  |  |  |  |  | 5,000,000 |  | 5,000,000 |  |  |  |  |
Clinical milestone payments under agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 5,000,000
Offset to research and development costs under collaboration arrangement | 300,000 | 400,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Expected development period |  | 82 months |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Review period |  | 30 days |  |  |  |  |  |  |  |  |  |  |  |  | 30 days |  |
Milestones under agreement |  |  |  |  |  | 0 |  | 0 |  |  |  |  |  |  |  |  |
Deferred revenue included in current liabilities | 20,684,000 | 20,684,000 | 20,267,000 |  |  |  |  |  |  | 7,300,000 |  | 7,300,000 |  | 8,600,000 |  |  |
Deferred revenue included in long-term liabilities | 23,912,000 | 23,912,000 | 7,136,000 |  |  |  |  |  |  | 12,100,000 |  | 12,100,000 |  | 800,000 |  |  |
Additional milestone payment due |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 5,000,000 |  |

X
- Definition Additional Clinical Milestone Payments Received + References No definition available. + Details
Name: | mgnx_AdditionalClinicalMilestonePaymentsReceived
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Aggregate potential clinical milestone payments available to be earned under collaboration agreement. + References No definition available. + Details
Name: | mgnx_AdditionalClinicalMilestonePaymentsUnderAgreement
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Additional license grant fees under agreement. + References No definition available. + Details
Name: | mgnx_AdditionalLicenseGrantFeesUnderAgreement
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Additional Milestone Payment + References No definition available. + Details
Name: | mgnx_AdditionalMilestonePayment
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Additional potential milestone payments receivable upon new drug application acceptance. + References No definition available. + Details
Name: | mgnx_AdditionalPotentialMilestonePaymentsReceivableUponNewDrugApplicationAcceptance
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Aggregate potential remaining regulatory milestone payments available to be earned under a collaboration arrangement. + References No definition available. + Details
Name: | mgnx_AdditionalRegulatoryMilestonePaymentsUnderAgreement
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Aggregate potential remaining sales milestone payments available to be earned under collaboration agreement. + References No definition available. + Details
Name: | mgnx_AdditionalSalesMilestonesUnderAgreement
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Collaboration and license agreement entered date. + References No definition available. + Details
Name: | mgnx_CollaborationAndLicenseAgreementEnteredDate
Namespace Prefix: | mgnx_
Data Type: | us-types:dateStringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaboration arrangement offset to research and development costs. + References No definition available. + Details
Name: | mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaborative arrangement expected development period. + References No definition available. + Details
Name: | mgnx_CollaborativeArrangementExpectedDevelopmentPeriod
Namespace Prefix: | mgnx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | mgnx_LicenseAndCollaborationAgreementsLineItems
Namespace Prefix: | mgnx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Milestone Payment + References No definition available. + Details
Name: | mgnx_MilestonePayment
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Initial fee received from collaboration or license agreement. + References No definition available. + Details
Name: | mgnx_NonRefundableFees
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Review period by regulatory authority. + References No definition available. + Details
Name: | mgnx_ReviewPeriodByRegulatoryAuthority
Namespace Prefix: | mgnx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Upfront payment recognition period. + References No definition available. + Details
Name: | mgnx_UpfrontPaymentRecognitionPeriod
Namespace Prefix: | mgnx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 + Details
Name: | us-gaap_DeferredRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A + Details
Name: | us-gaap_DeferredRevenueCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A + Details
Name: | us-gaap_DeferredRevenueNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(e)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details
Name: | us-gaap_LicensesRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Cash received from licensees for license fees during the current period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585 + Details
Name: | us-gaap_ProceedsFromLicenseFeesReceived
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration